Day: September 11, 2023

Samsung Bioepis Partners with Sandoz to Commercialize Ustekinumab Biosimilar Candidate

Enters into a commercialization agreement for SB17, ustekinumab biosimilar candidate, in Europe and North America Partnership to support Samsung Bioepis pipeline expansion and provide increased access to biosimilars INCHEON, Korea, Sept. 11, 2023 (GLOBE NEWSWIRE) — Samsung Bioepis Co., Ltd. today announced that it has entered into a commercialization agreement with Sandoz for SB17, a […]

Continue Reading »